Erythropoietin prevents dementia in hemodialysis patients: A nationwide population-based study

Peir Haur Hung, Chih Ching Yeh, Fung Chang Sung, Chih Yen Hsiao, Chih Hsin Muo, Kuan Yu Hung, Kuen Jer Tsai

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.

Original languageEnglish
Pages (from-to)6941-6950
Number of pages10
Issue number17
Publication statusPublished - Sept 1 2019


  • Alzheimer's disease
  • End-stage renal disease
  • Erythropoietin
  • Hemodialysis

ASJC Scopus subject areas

  • Ageing
  • Cell Biology


Dive into the research topics of 'Erythropoietin prevents dementia in hemodialysis patients: A nationwide population-based study'. Together they form a unique fingerprint.

Cite this